4967:TSEKobayashi Pharmaceutical Co., Ltd. Analysis

Kobayashi Pharmaceutical is trading at ¥5,925, comfortably above its 20‑day (¥5,842) and 50‑day (¥5,823) SMAs and even the 200‑day SMA (¥5,492), indicating a solid bullish bias. The MACD histogram is positive (≈7.55) and the signal line is bullish, while the RSI sits at 56, suggesting room for upside without immediate overbought pressure. Volume is on an upward trend, support sits near ¥5,707 and resistance near ¥5,985, and the market sentiment index flags “Extreme Greed,” all pointing to short‑term momentum strength.
On the fundamentals side, the stock carries an eye‑popping trailing PE of 120× versus a forward PE of about 25×, reflecting current overvaluation that may compress as earnings catch up. Revenue is growing modestly at 3.2% YoY, margins are thin (gross 51%, operating 3.9%, profit 1.8%), and ROE is only 1.5%, underscoring limited profitability. The dividend payout ratio exceeds 200%, raising questions about sustainability despite a 1.79% yield. Nevertheless, the balance sheet is strong with ample cash and low debt, and the consumer‑defensive sector offers stability.